WO2023019223A3 - METHODS OF REDUCING PRODUCTION OF IgA, IgM AND/OR IgG USING sBCMA VARIANTS AND FC FUSION PROTEINS THEREOF - Google Patents

METHODS OF REDUCING PRODUCTION OF IgA, IgM AND/OR IgG USING sBCMA VARIANTS AND FC FUSION PROTEINS THEREOF Download PDF

Info

Publication number
WO2023019223A3
WO2023019223A3 PCT/US2022/074868 US2022074868W WO2023019223A3 WO 2023019223 A3 WO2023019223 A3 WO 2023019223A3 US 2022074868 W US2022074868 W US 2022074868W WO 2023019223 A3 WO2023019223 A3 WO 2023019223A3
Authority
WO
WIPO (PCT)
Prior art keywords
sbcma
iga
igm
igg
variants
Prior art date
Application number
PCT/US2022/074868
Other languages
French (fr)
Other versions
WO2023019223A2 (en
Inventor
Amato J. Giaccia
Yu MIAO
Xin Eric ZHANG
Original Assignee
Akso Biopharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akso Biopharmaceutical Inc. filed Critical Akso Biopharmaceutical Inc.
Priority to AU2022327178A priority Critical patent/AU2022327178A1/en
Priority to EP22856825.9A priority patent/EP4384201A2/en
Priority to CN202280067600.2A priority patent/CN118678963A/en
Priority to CA3228678A priority patent/CA3228678A1/en
Priority to JP2024508471A priority patent/JP2024529128A/en
Priority to KR1020247007973A priority patent/KR20240053675A/en
Publication of WO2023019223A2 publication Critical patent/WO2023019223A2/en
Publication of WO2023019223A3 publication Critical patent/WO2023019223A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

This invention is directed to methods of reducing immunoglobulin production (e.g. IgA, IgM, and/or IgG, etc.) in subjects diagnosed with an autoimmune disease and/or fibrosis comprising administering to the subjects compositions comprising sBCMA variants and/or sBCMA variant – Fc fusion proteins.
PCT/US2022/074868 2021-08-11 2022-08-11 METHODS OF REDUCING PRODUCTION OF IgA, IgM AND/OR IgG USING sBCMA VARIANTS AND FC FUSION PROTEINS THEREOF WO2023019223A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2022327178A AU2022327178A1 (en) 2021-08-11 2022-08-11 METHODS OF REDUCING PRODUCTION OF IgA, IgM AND/OR IgG USING sBCMA VARIANTS AND FC FUSION PROTEINS THEREOF
EP22856825.9A EP4384201A2 (en) 2021-08-11 2022-08-11 Methods of reducing production of iga, igm and/or igg using sbcma variants and fc fusion proteins thereof
CN202280067600.2A CN118678963A (en) 2021-08-11 2022-08-11 Methods of reducing IgA, igM and/or IgG production using sBCMA variants and FC fusion proteins thereof
CA3228678A CA3228678A1 (en) 2021-08-11 2022-08-11 Methods of reducing production of iga, igm and/or igg using sbcma variants and fc fusion proteins thereof
JP2024508471A JP2024529128A (en) 2021-08-11 2022-08-11 Methods for reducing IgA, IgM, and/or IgG production using sBCMA variants and their FC fusion proteins
KR1020247007973A KR20240053675A (en) 2021-08-11 2022-08-11 Method for reducing production of IgA, IgM and/or IgG using sBCMA variants and FC fusion proteins thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163232124P 2021-08-11 2021-08-11
US63/232,124 2021-08-11

Publications (2)

Publication Number Publication Date
WO2023019223A2 WO2023019223A2 (en) 2023-02-16
WO2023019223A3 true WO2023019223A3 (en) 2023-09-28

Family

ID=85200996

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/074868 WO2023019223A2 (en) 2021-08-11 2022-08-11 METHODS OF REDUCING PRODUCTION OF IgA, IgM AND/OR IgG USING sBCMA VARIANTS AND FC FUSION PROTEINS THEREOF

Country Status (7)

Country Link
EP (1) EP4384201A2 (en)
JP (1) JP2024529128A (en)
KR (1) KR20240053675A (en)
CN (1) CN118678963A (en)
AU (1) AU2022327178A1 (en)
CA (1) CA3228678A1 (en)
WO (1) WO2023019223A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150017164A1 (en) * 2007-03-27 2015-01-15 Zymogenetics, Inc. COMBINATION OF BLyS AND/OR APRIL INHIBITION AND IMMUNOSUPPRESSANTS FOR TREATMENT OF AUTOIMMUNE DISEASE
US20150098953A1 (en) * 2003-10-20 2015-04-09 Biogen Idec Ma Inc. Methods of treating a patient having an autoimmune disorder by administering a baff antagonist
US20200197529A1 (en) * 2011-05-27 2020-06-25 Glaxo Group Limited Antigen binding proteins
WO2020245182A1 (en) * 2019-06-04 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for modulating immunoglobulin expression
WO2022036009A1 (en) * 2020-08-12 2022-02-17 The Board Of Trustees Of The Leland Stanford Junior University Sbcma variants and fc fusion proteins thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200000147A (en) 1997-09-12 2001-02-15 Biogen, Incorporated April - a new growth protein
EP1028306B1 (en) 1998-08-28 2008-10-15 Mitutoyo Corporation Apparatus and method concerning analysis and generation of a part program for measuring coordinates and surface properties
MXPA02001665A (en) 1999-08-17 2003-07-14 Biogen Inc Baff receptor (bcma), an immunoregulatory agent.
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150098953A1 (en) * 2003-10-20 2015-04-09 Biogen Idec Ma Inc. Methods of treating a patient having an autoimmune disorder by administering a baff antagonist
US20150017164A1 (en) * 2007-03-27 2015-01-15 Zymogenetics, Inc. COMBINATION OF BLyS AND/OR APRIL INHIBITION AND IMMUNOSUPPRESSANTS FOR TREATMENT OF AUTOIMMUNE DISEASE
US20200197529A1 (en) * 2011-05-27 2020-06-25 Glaxo Group Limited Antigen binding proteins
WO2020245182A1 (en) * 2019-06-04 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for modulating immunoglobulin expression
WO2022036009A1 (en) * 2020-08-12 2022-02-17 The Board Of Trustees Of The Leland Stanford Junior University Sbcma variants and fc fusion proteins thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHU ET AL.: "B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1", PNAS, vol. 97, no. 16, 1 August 2000 (2000-08-01), pages 9156 - 9161, XP002160851, DOI: 10.1073/pnas.160213497 *

Also Published As

Publication number Publication date
CN118678963A (en) 2024-09-20
AU2022327178A1 (en) 2024-03-28
WO2023019223A2 (en) 2023-02-16
JP2024529128A (en) 2024-08-01
CA3228678A1 (en) 2023-02-16
EP4384201A2 (en) 2024-06-19
KR20240053675A (en) 2024-04-24

Similar Documents

Publication Publication Date Title
Hu et al. Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE+ B cells
ECSP066379A (en) ANTIBODIES RG1 AND USES OF THE SAME
EA202092933A1 (en) ANTIBODIES TO ENTPD2, TYPES OF COMBINATION THERAPY AND METHODS OF APPLICATION OF ANTIBODIES AND TYPES OF COMBINATION THERAPY
EP2267032A3 (en) Method of administering therapeutic polypeptides, and polypeptides therefor
KR102687512B1 (en) anti-human annexin A1 antibody
WO2004029093A3 (en) Humanized anti-granulocyte mn-3 antibody and uses thereof
DOP2009000221A (en) UNION PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, WHICH SPECIFICALLY JOIN CD154 AND ITS USES
RU2003129528A (en) METHOD FOR EXPRESSION OF PROTEINS CONTAINING AN ANTIBODY HYBRID ISOTYPE AS A COMPONENT
PE20090766A1 (en) HUMANIZED IGG1 ANTIBODY
PE20080100A1 (en) ANTIBODIES BLOCKING THE FUNCTION OF INTEGRIN a5ß1, HUMAN AND HUMANIZED, WITH HIGH AFFINITY WITH REDUCED IMMUNOGENICITY
NO20074554L (en) Antigen binding molecules targeting MCSP and which have enhanced FC receptor binding affinity and effector function
AU2015255979B2 (en) Using B-cell-targeting antigen IgG fusion as tolerogenic protein therapy for treating adverse immune responses
BR112023024494A2 (en) ENGINEERED POLYPEPTIDES
WO2008100470A3 (en) Rage - immunoglobulin fusion proteins
EA202190378A1 (en) ANTIBODIES AGAINST IFNAR1 FOR THE TREATMENT OF AUTOIMMUNE DISEASES
JP2016531546A (en) Methods for analyzing immunoglobulin molecular samples
MX2021002208A (en) Cd80 extracellular domain fc fusion protein dosing regimens.
EP3994275A4 (en) Recombinant human sialidases, sialidase fusion proteins, and methods of using the same
MXPA03011499A (en) Fce fusion proteins for treatment of allergy and asthma.
EA202090084A1 (en) NEW THERAPEUTIC ENZYME Fusion PROTEIN AND ITS APPLICATION
WO2021252974A3 (en) Collagen-targeted fusion proteins and antibodies
WO2023019223A3 (en) METHODS OF REDUCING PRODUCTION OF IgA, IgM AND/OR IgG USING sBCMA VARIANTS AND FC FUSION PROTEINS THEREOF
EA202092458A1 (en) COMPOSITIONS BASED ON RECOMBINANT FUSED PROTEIN CONTAINING HUMAN NEUREGULIN-1 (NRG-1), AND METHODS FOR THEIR APPLICATION
MX2023005313A (en) Fcrn antibodies and methods of use thereof.
MX2022001380A (en) Fcrn antibodies and methods of use thereof.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22856825

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2024508471

Country of ref document: JP

Ref document number: 3228678

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 20247007973

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2022327178

Country of ref document: AU

Ref document number: 808949

Country of ref document: NZ

Ref document number: AU2022327178

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022856825

Country of ref document: EP

Effective date: 20240311

ENP Entry into the national phase

Ref document number: 2022327178

Country of ref document: AU

Date of ref document: 20220811

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11202400932T

Country of ref document: SG

WWE Wipo information: entry into national phase

Ref document number: 202280067600.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22856825

Country of ref document: EP

Kind code of ref document: A2